Search Results - Ruckel-Kumar, Julie

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    P688: ASC2ESCALATE: A US PHASE 2, OPEN‐LABEL, SINGLE‐ARM, DOSE‐ESCALATION STUDY OF ASCIMINIB MONOTHERAPY IN 2ND‐LINE (2L) TREATMENT OF PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML‐CP)

    P688: ASC2ESCALATE: A US PHASE 2, OPEN‐LABEL, SINGLE‐ARM, DOSE‐ESCALATION STUDY OF ASCIMINIB MONOTHERAPY IN 2ND‐LINE (2L) TREATMENT OF PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA... by Atallah, Ehab, Mauro, Michael, Sasaki, Koji, Yair Levy, Moshe, Koller, Paul, Sadek, Islam, Yang, Daisy, Ruckel‐Kumar, Julie, Khan, Mahmudul, Cortes, Jorge

    Published in HemaSphere
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Sabatolimab in Combination with Hypomethylating Agents (HMAs) Was Safe in Patients (Pts) with Intermediate-, High-, or Very-High-Risk Myelodysplastic Syndrome (MDS)

    Sabatolimab in Combination with Hypomethylating Agents (HMAs) Was Safe in Patients (Pts) with Intermediate-, High-, or Very-High-Risk Myelodysplastic Syndrome (MDS) by Garcia-Manero, Guillermo, Lyons, Roger M., Nandal, Savita, Ashraf, Mushtaq, Thellaboina, Ramarao, Ruckel-Kumar, Julie, Menssen, Hans D., Zeidan, Amer M.

    Published in Blood
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: